Gyre Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Gyre Therapeutics, Inc. (GYRE) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $181.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-07
- Gyre Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was -$502.00K.
- Gyre Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was $683.00K, a 84.62% decline year-over-year.
- Gyre Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $2.38M, a 13.98% increase year-over-year.
- Gyre Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was -$3.86M.
- Gyre Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $946.00K.
- Gyre Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was -$1.50M, a 203.53% decline from fiscal 2023.
- Gyre Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $1.45M, a 24.45% decline from fiscal 2022.
- Gyre Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $1.91M.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$502.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $181.00K 10-Q · filed 2026-08-07 | $2.56M derived: sum of 3 quarters · filed 2026-08-07 | -$1.30M derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2026-03-31 | $683.00K 10-Q · filed 2026-05-08 | $3.06M derived: sum of 2 quarters · filed 2026-05-08 | -$794.00K derived: sum of 3 quarters · filed 2026-05-08 | -$2.81M derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2025-12-31 | $2.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$1.48M derived: sum of 2 quarters · filed 2026-03-13 | -$3.50M derived: sum of 3 quarters · filed 2026-08-07 | $946.00K 10-K · filed 2026-03-13 | |||
| 2025-09-30 | -$3.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$5.88M derived: sum of 2 quarters · filed 2026-08-07 | -$1.43M 10-Q · filed 2025-11-07 | $654.00K derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2025-06-30 | -$2.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $2.42M 10-Q · filed 2026-08-07 | $2.08M 10-Q · filed 2025-08-11 | $4.51M derived: sum of 3 quarters · filed 2026-08-07 | $2.96M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-03-31 | $4.44M 10-Q · filed 2026-05-08 | $6.53M derived: sum of 2 quarters · filed 2026-05-08 | $4.98M derived: sum of 3 quarters · filed 2026-05-08 | $4.91M derived: sum of 4 quarters · filed 2026-05-08 | |||
| 2024-12-31 | $2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $541.00K derived: sum of 2 quarters · filed 2026-03-13 | $471.00K derived: sum of 3 quarters · filed 2026-03-13 | -$1.50M 10-K · filed 2026-03-13 | |||
| 2024-09-30 | -$1.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$1.62M derived: sum of 2 quarters · filed 2025-11-07 | -$3.58M 10-Q · filed 2025-11-07 | -$3.50M 10-Q · filed 2024-11-13 | -$2.09M derived: sum of 4 quarters · filed 2025-11-07 | ||
| 2024-06-30 | -$70.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$2.04M 10-Q · filed 2025-08-11 | -$2.17M 10-Q · filed 2024-08-13 | -$546.00K derived: sum of 3 quarters · filed 2025-08-11 | -$3.55M derived: sum of 4 quarters · filed 2025-08-11 | ||
| 2024-03-31 | -$1.97M 10-Q · filed 2025-05-09 | -$1.84M 10-Q · filed 2024-05-13 | -$476.00K derived: sum of 2 quarters · filed 2025-05-09 | -$3.48M derived: sum of 3 quarters · filed 2025-05-09 | -$1.55M derived: sum of 4 quarters · filed 2025-05-09 | ||
| 2023-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$1.51M derived: sum of 2 quarters · filed 2025-03-17 | $418.00K derived: sum of 3 quarters · filed 2025-03-17 | $1.45M 10-K · filed 2025-03-17 | |||
| 2023-09-30 | -$3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$1.07M derived: sum of 2 quarters · filed 2024-11-13 | -$46.00K 10-Q · filed 2024-11-13 | ||||
| 2023-06-30 | $1.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $2.96M 10-Q · filed 2024-08-13 | |||||
| 2023-03-31 | $1.03M 10-Q · filed 2024-05-13 | ||||||
| 2022-12-31 | $1.91M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |